Cargando…

Neuroprotective Agents with Therapeutic Potential for COVID-19

COVID-19 patients can exhibit a wide range of clinical manifestations affecting various organs and systems. Neurological symptoms have been reported in COVID-19 patients, both during the acute phase of the illness and in cases of long-term COVID. Moderate symptoms include ageusia, anosmia, altered m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaa, César A., Espitia, Clara, Reyes-Barrera, Karen L., An, Zhiqiang, Velasco-Velázquez, Marco A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669388/
https://www.ncbi.nlm.nih.gov/pubmed/38002267
http://dx.doi.org/10.3390/biom13111585
_version_ 1785139684938088448
author Zaa, César A.
Espitia, Clara
Reyes-Barrera, Karen L.
An, Zhiqiang
Velasco-Velázquez, Marco A.
author_facet Zaa, César A.
Espitia, Clara
Reyes-Barrera, Karen L.
An, Zhiqiang
Velasco-Velázquez, Marco A.
author_sort Zaa, César A.
collection PubMed
description COVID-19 patients can exhibit a wide range of clinical manifestations affecting various organs and systems. Neurological symptoms have been reported in COVID-19 patients, both during the acute phase of the illness and in cases of long-term COVID. Moderate symptoms include ageusia, anosmia, altered mental status, and cognitive impairment, and in more severe cases can manifest as ischemic cerebrovascular disease and encephalitis. In this narrative review, we delve into the reported neurological symptoms associated with COVID-19, as well as the underlying mechanisms contributing to them. These mechanisms include direct damage to neurons, inflammation, oxidative stress, and protein misfolding. We further investigate the potential of small molecules from natural products to offer neuroprotection in models of neurodegenerative diseases. Through our analysis, we discovered that flavonoids, alkaloids, terpenoids, and other natural compounds exhibit neuroprotective effects by modulating signaling pathways known to be impacted by COVID-19. Some of these compounds also directly target SARS-CoV-2 viral replication. Therefore, molecules of natural origin show promise as potential agents to prevent or mitigate nervous system damage in COVID-19 patients. Further research and the evaluation of different stages of the disease are warranted to explore their potential benefits.
format Online
Article
Text
id pubmed-10669388
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106693882023-10-27 Neuroprotective Agents with Therapeutic Potential for COVID-19 Zaa, César A. Espitia, Clara Reyes-Barrera, Karen L. An, Zhiqiang Velasco-Velázquez, Marco A. Biomolecules Review COVID-19 patients can exhibit a wide range of clinical manifestations affecting various organs and systems. Neurological symptoms have been reported in COVID-19 patients, both during the acute phase of the illness and in cases of long-term COVID. Moderate symptoms include ageusia, anosmia, altered mental status, and cognitive impairment, and in more severe cases can manifest as ischemic cerebrovascular disease and encephalitis. In this narrative review, we delve into the reported neurological symptoms associated with COVID-19, as well as the underlying mechanisms contributing to them. These mechanisms include direct damage to neurons, inflammation, oxidative stress, and protein misfolding. We further investigate the potential of small molecules from natural products to offer neuroprotection in models of neurodegenerative diseases. Through our analysis, we discovered that flavonoids, alkaloids, terpenoids, and other natural compounds exhibit neuroprotective effects by modulating signaling pathways known to be impacted by COVID-19. Some of these compounds also directly target SARS-CoV-2 viral replication. Therefore, molecules of natural origin show promise as potential agents to prevent or mitigate nervous system damage in COVID-19 patients. Further research and the evaluation of different stages of the disease are warranted to explore their potential benefits. MDPI 2023-10-27 /pmc/articles/PMC10669388/ /pubmed/38002267 http://dx.doi.org/10.3390/biom13111585 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zaa, César A.
Espitia, Clara
Reyes-Barrera, Karen L.
An, Zhiqiang
Velasco-Velázquez, Marco A.
Neuroprotective Agents with Therapeutic Potential for COVID-19
title Neuroprotective Agents with Therapeutic Potential for COVID-19
title_full Neuroprotective Agents with Therapeutic Potential for COVID-19
title_fullStr Neuroprotective Agents with Therapeutic Potential for COVID-19
title_full_unstemmed Neuroprotective Agents with Therapeutic Potential for COVID-19
title_short Neuroprotective Agents with Therapeutic Potential for COVID-19
title_sort neuroprotective agents with therapeutic potential for covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669388/
https://www.ncbi.nlm.nih.gov/pubmed/38002267
http://dx.doi.org/10.3390/biom13111585
work_keys_str_mv AT zaacesara neuroprotectiveagentswiththerapeuticpotentialforcovid19
AT espitiaclara neuroprotectiveagentswiththerapeuticpotentialforcovid19
AT reyesbarrerakarenl neuroprotectiveagentswiththerapeuticpotentialforcovid19
AT anzhiqiang neuroprotectiveagentswiththerapeuticpotentialforcovid19
AT velascovelazquezmarcoa neuroprotectiveagentswiththerapeuticpotentialforcovid19